Over the past 30 years, cord blood and cord tissue have gained popularity and commercial traction due to the valuable stem cells they contain. According to ClinicalTrials.gov, there are over 1,360 clinical trials evaluating the use of cord blood and tissue-derived cells. These studies typically leverage unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs). [Read more…]
Americord® Releases Exosomes Banking with CryoMaxx™ Processing
Americord Registry announces the addition of exosome banking to their suite services, becoming the first company in the United States to do so.
NEW YORK, NEW YORK, US, October 11, 2022 – Americord Registry®, a leader in the cord blood industry, announced the addition of exosome banking to their suite of family-focused services, becoming the first private biobanking company in the United States to do so. Exosomes are tiny, extracellular vesicles that initiate cell-to-cell communication by shuttling cellular components to other cells. Pre-clinical research has shown that exosomes may regulate immune responses, wound healing, and cell growth and development. [Read more…]
Placental Stem Cells – Interview with Dr. Ornella Parolini of IPLASS
In this interview with Dr. Ornella Parolini, Director of the E. Menni Research Center in Italy, we discussed her pioneering research on human placental stem cells. Her research is focused on the immunomodulatory and anti-inflammatory properties of amniotic and chorionic membrane cells. She is also President of the International Placenta Stem Cell Society (IPLASS), making her a globally recognized expert.
In addition to Dr. Robert Harari who holds a wide range of placental stem cell patents, Dr. Parolini is one of the world’s leading experts on placental stem cells and their therapeutic applications.
In this article:
Cord Blood Market Segmentation in 2022
Cord blood market segmentation is one of the most important (and least appreciated) parts of analyzing the cord blood banking industry. As the first and only market research firm to track the stem cell industry, BioInformant has collected over 16 years of historical information on the cord blood industry from 2006 to present. This provides a powerful record if past industry dynamics, as well as a robust platform for making future projections. [Read more…]
How the Cord Blood and Tissue Market is Changing
The global cord blood and tissue banking market is consolidating, driven by the emergence of holding companies and aggressive M&A activity. This is creating risks for cord blood market participants, as well as new opportunities.
Serious threats to the industry include:
- Low rates of stored cord blood utilization
- Utilization of bone marrow and peripheral blood stem cells as alternative sources of stem cells for HSCT
- Growing prevalence of haploidentical transplantation
- Expensive transplant procedures, ranging from $200-300K
- Difficulty educating Obstetricians about the future value of cellular therapies
- Low rates of market penetration
- Low rates of cord blood awareness among expectant parents
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 31
- Next Page »